Payment overview · 2025
General Payments
$135.57
7 reported records · 6 companies
Healthcare provider profile · identity verified
Jimmy W Dailey, MD
Allopathic & Osteopathic Physicians|Family Medicine · CANTON, TX · NPI 1073598199
Verified facts
What the public records show
CMS Open Payments records show Jimmy W Dailey, MD received $135.57 in general payments during 2025 across 7 reported records.
Lilly USA, LLC accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.71 | 21.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.17 | 18.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.89 | 18.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.47 | 16.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.63 | 13.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.70 | 10.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $135.57 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 256 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
256 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 530 | 186 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 428 | 68 |
| Furosemide | Furosemide | 392 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 103 |
| Potassium Chloride | Potassium Chloride | 338 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 337 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 110 |
| Gabapentin | Gabapentin | 317 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 300 | 103 |
| Losartan Potassium | Losartan Potassium | 262 | 92 |
| Eliquis | Apixaban | 256 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 253 | 72 |
| Tramadol Hcl | Tramadol Hcl | 251 | 64 |
| Sertraline Hcl | Sertraline Hcl | 236 | 56 |
| Lisinopril | Lisinopril | 232 | 80 |
| Carvedilol | Carvedilol | 219 | 63 |
| Donepezil Hcl | Donepezil Hcl | 212 | 34 |
| Alprazolam | Alprazolam | 206 | 38 |
| Metformin Hcl | Metformin Hcl | 190 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 188 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 48 |
| Omeprazole | Omeprazole | 184 | 68 |
| Montelukast Sodium | Montelukast Sodium | 174 | 48 |
| Trazodone Hcl | Trazodone Hcl | 172 | 57 |
| Ozempic | Semaglutide | 162 | 38 |
| Jardiance | Empagliflozin | 154 | 29 |
| Buprenorphine Hcl | Buprenorphine Hcl | 152 | 29 |
| Buspirone Hcl | Buspirone Hcl | 152 | 29 |
| Prednisone | Prednisone | 145 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 38 |
| Simvastatin | Simvastatin | 125 | 41 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 121 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 50 |
| Lorazepam | Lorazepam | 118 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 114 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 23 |
| Celecoxib | Celecoxib | 103 | 40 |
| Divalproex Sodium | Divalproex Sodium | 102 | 18 |
| Mirtazapine | Mirtazapine | 102 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 27 |
| Testosterone Cypionate | Testosterone Cypionate | 92 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 23 |
| Ezetimibe | Ezetimibe | 84 | 28 |
| Memantine Hcl | Memantine Hcl | 81 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 81 | 14 |
| Irbesartan | Irbesartan | 79 | 31 |
| Xarelto | Rivaroxaban | 76 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 30 |
| Pregabalin | Pregabalin | 71 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 28 |
| Finasteride | Finasteride | 69 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 17 |
| Allopurinol | Allopurinol | 66 | 22 |
| Spironolactone | Spironolactone | 66 | 22 |
| Clonazepam | Clonazepam | 65 | 12 |
| Myrbetriq | Mirabegron | 65 | 20 |
| Temazepam | Temazepam | 65 | 13 |
| Doxepin Hcl | Doxepin Hcl | 64 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 28 |
| Glipizide Er | Glipizide | 59 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 15 |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 15 |
| Trulicity | Dulaglutide | 54 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 13 |
| Methylprednisolone | Methylprednisolone | 51 | 47 |
| Famotidine | Famotidine | 50 | 20 |
| Glipizide | Glipizide | 50 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 34 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 49 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Chlorthalidone | Chlorthalidone | 47 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 13 |
| Ondansetron Odt | Ondansetron | 46 | 17 |
| Valsartan | Valsartan | 46 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 27 |
| Methocarbamol | Methocarbamol | 44 | 17 |
| Meloxicam | Meloxicam | 43 | 21 |
| Nystatin | Nystatin | 43 | 26 |
| Aripiprazole | Aripiprazole | 42 | 12 |
| Azithromycin | Azithromycin | 42 | 36 |
| Cefdinir | Cefdinir | 42 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 13 |
| Sucralfate | Sucralfate | 42 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 37 | suppressed |
| Metolazone | Metolazone | 37 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 25 |
| Midodrine Hcl | Midodrine Hcl | 35 | 12 |
| Baclofen | Baclofen | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Fentanyl | Fentanyl | 32 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 11 |
| Ramipril | Ramipril | 31 | 12 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 12 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | 11 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Rytary | Carbidopa/Levodopa | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 15 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Trandolapril | Trandolapril | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $135.57 · 7 records | Lilly USA, LLC | ELIQUIS, MCOT, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, TRELEGY ELLIPTA, Veozah, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error